Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Fig. 3

3A, PFS according to PD-L1 CPS classes; 3B, OS according to PD-L1 CPS classes; 3C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3E, PFS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes; 3F, OS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us